Skip to content

Cardiovascular Protective Role of Laser Acupuncture in Systemic Lupus

Cardiovascular Protective Role of Laser Acupuncture in Systemic Lupus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04970199
Enrollment
60
Registered
2021-07-21
Start date
2021-07-12
Completion date
2021-11-30
Last updated
2022-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

System; Lupus Erythematosus

Brief summary

Systemic lupus erythematosus is a chronic and multisystemic autoimmune disorder which predominantly affecting women. The most common cause of death in lupus patients affected by disease for more than 5 years is cardiovascular disease due to presence of some factors as oxidative stress, pro-inflammatory cytokines , dyslipidemia, diabetes, and hypertension.

Detailed description

laser acupuncture (active or sham) for one month (3 days/week ) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser will be applied for 1 min on every acupiont) in lupus females

Interventions

DEVICElaser application on acupoints

laser acupuncture

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 47 Years
Healthy volunteers
No

Inclusion criteria

* lupus females * 60 patients

Exclusion criteria

* pregnancy * cardiovascular diseases * respiratory diseases

Design outcomes

Primary

MeasureTime frameDescription
MalondialdehydeIt was measured after 4 weeksanti-oxidative stress factor

Secondary

MeasureTime frameDescription
diastoleIt was measured after 4 weeksblood pressure
blood glucoseIt was be measured after 4 weeksfasting
erythrocyte sedimentation rate (1 hour)It was measured after 4 weeksinflammatory marker
erythrocyte sedimentation rate (2 hour)It was measured after 4 weeksinflammatory marker
systoleIt was measured after 4 weeksblood pressure
adenosine triphosphateIt was measured after 4 weeksenergy production marker
NitrateIt was measured after 4 weeksoxidative stress factor
GlutathioneIt was measured after 4 weeksantioxidant marker
c reactive proteinIt was measured after 4 weeksinflammatory marker

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026